Here are what the editors at HealthDay consider to be the most important developments in Rheumatology for November 2018. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Higher Cardiovascular Risk Seen With Psoriatic Arthritis
FRIDAY, Nov. 30, 2018 (HealthDay News) — Cardiovascular risk should be carefully evaluated in patients with psoriatic arthritis, according to a study published online Nov. 5 in the International Journal of Rheumatic Diseases.
Abstract/Full Text (subscription or payment may be required)
FDA to Update Medical Device Approvals Process
TUESDAY, Nov. 27, 2018 (HealthDay News) — A major update of the United States’ system for approving medical devices was announced yesterday by the Food and Drug Administration.
CBS/AP News Article
More Information
Four Principles Underlie Patient and Family Partnership in Care
TUESDAY, Nov. 27, 2018 (HealthDay News) — Patient and family partnership in care should include treatment of patients and families with dignity and respect, their active engagement in all aspects of care, and their contribution to the improvement of health care systems and education of health care professionals, according to a position paper published online Nov. 27 in the Annals of Internal Medicine.
Position Paper
Editorial (subscription or payment may be required)
ACA Coverage Substantial, but Did Not Impact Labor Markets
MONDAY, Nov. 26, 2018 (HealthDay News) — Millions of workers gained insurance coverage under the Affordable Care Act (ACA) without adverse effects on labor markets, according to a report published by the Robert Wood Johnson Foundation and the Urban Institute.
Report: How Have Workers Fared Under the ACA?
FDA Approves Drug to Treat Rare Immune Disease
WEDNESDAY, Nov. 21, 2018 (HealthDay News) — The U.S. Food and Drug Administration on Monday approved Gamifant (emapalumab-lzsg) for the treatment of primary hemophagocytic lymphohistiocytosis (HLH) in pediatric (as young as newborn) and adult patients who have refractory, recurrent, or progressive disease or intolerance with conventional HLH treatment.
Bone Erosions More Frequent With Old Age at Onset of Early RA
WEDNESDAY, Nov. 21, 2018 (HealthDay News) — Old age at onset of early rheumatoid arthritis (RA) is associated with more frequent bone erosions, according to a study published online Nov. 11 in the International Journal of Rheumatic Diseases.
Abstract/Full Text (subscription or payment may be required)
CDC: 8.8 Percent Uninsured in U.S. in First Half of 2018
FRIDAY, Nov. 16, 2018 (HealthDay News) — In the first six months of 2018, 8.8 percent of U.S. individuals of all ages were uninsured, which was not significantly different from 2017, according to a report published Nov. 15 by the U.S. Centers for Disease Control and Prevention National Center for Health Statistics.
Drug Retention in Spondyloarthritis Varies With Socioeconomic Status 
Nearly Half of Adults With Arthritis Have Arthritis-Attributable Activity Limitations 
COPD Tied to Increased Risk for Death in Patients With Arthritis 
Overactive Bladder Positively Associated With Arthritis 
Updated COVID-19 Shot Beneficial for Those With Autoimmune Rheumatic Disease 
Distinct Characteristics ID"d for Patients With Rheumatoid Conditions, Opioid Use Disorder 
Exposure to Air Pollutants Linked to Increased RA Disease Activity 
Review Reveals Limited Effects of Exercise on Hip Osteoarthritis 
.jpg)